Webinar: Innovations in drug delivery - tune in and join our excellent panel

By Liza Laws

- Last updated on GMT

© Getty Images
© Getty Images
As the landscape of healthcare continues to evolve, so too does the field of drug delivery.

Gone are the days when oral methods were the primary means of administering medication.

Today, continuous innovations have expanded the arsenal of delivery methods to include implants, patches, syringes, and various solutions for transdermal, topical, and oral systems.

These advancements not only cater to diverse health needs but also address the challenges posed by an aging population, the prevalence of chronic diseases, and the increasing demand for patient-centric care.

To delve deeper into the realm of innovations in drug delivery, we invite you to join​ our upcoming webinar, scheduled for tomorrow (February 28) at 5PM CET (Paris) | 10AM CT (Chicago).

This webinar promises to be an enlightening session, featuring insights from a distinguished panel of industry experts who are at the forefront of driving innovation in this dynamic market.

Meet our speakers:

Gil Roth - president of Pharma & Biopharma Outsourcing Association (PBOA)

With a background in pharmaceutical outsourcing, Gil Roth brings a unique perspective to the discussion on drug delivery innovations. As the head of the Pharma & Biopharma Outsourcing Association (PBOA), Roth is committed to fostering collaboration and innovation within the industry. His insights into the evolving landscape of outsourcing and partnership models offer invaluable insights into the broader ecosystem of drug development and delivery.

Todd Asmuth - president and chief strategy officer at Shine Technology

Todd Asmuth is a visionary leader with a passion for driving technological innovations in drug delivery. At Shine Technology, he leads a dedicated team of researchers and engineers in developing next-generation delivery systems that offer precision, efficacy, and safety. Asmuth's deep understanding of market dynamics and patient needs positions him as a thought leader in the quest for transformative drug delivery solutions.

John Maher - chief scientific officer at Leucid Bio

With a career spanning over two decades in the pharmaceutical industry, John Maher brings a wealth of experience to the table. Currently serving as a key figure at Leucid Bio, Maher is renowned for his expertise in leveraging cutting-edge technologies to revolutionize drug delivery mechanisms. His insights into the latest trends and advancements in the field are invaluable for understanding the future trajectory of drug delivery innovations.

Cameron Owen - CEO and co-founder at rBIO

As a seasoned professional in the biotechnology sector, Cameron Owen has played a pivotal role in shaping the landscape of drug delivery solutions. At rBIO, Owen spearheads initiatives aimed at developing novel delivery platforms that enhance therapeutic outcomes and patient compliance. His expertise lies in bridging the gap between scientific innovation and commercial viability, making him a sought-after voice in the industry.

As we navigate the complexities of modern healthcare, the importance of innovation in drug delivery cannot be overstated. Join us for what is certain to be a lively and engaging webinar as we explore the latest advancements, challenges, and opportunities in this critical field. Don't miss this opportunity to gain insights from industry leaders and expand your understanding of the future of drug delivery.

If you miss the live webinar, it will be available for three months afterwards so be sure to share the link​ with your colleagues and associates. 

Related news

Show more

Related products

show more

Reliability, scale, and security of supply

Reliability, scale, and security of supply

Content provided by Univar Solutions USA | 28-Aug-2024 | Product Brochure

Univar Solutions Pharmaceutical Ingredients is proud to offer one of the most expansive portfolios of 15,000+ products, including high-purity solvents,...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers

Follow us

Products

View more

Webinars